Scholar Rock (SRRK) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Executive summary
The annual meeting will be held virtually on June 4, 2026, with shareholders able to vote online, by phone, mail, or QR code until June 3, 2026.
Shareholders will vote on electing four Class II directors, ratifying Deloitte & Touche LLP as auditor, and approving executive compensation on an advisory basis.
The Board recommends voting in favor of all proposals and emphasizes the importance of shareholder participation.
Voting matters and shareholder proposals
Proposal 1: Elect four Class II directors to serve until the 2029 annual meeting.
Proposal 2: Ratify Deloitte & Touche LLP as independent auditor for fiscal year ending December 31, 2026.
Proposal 3: Approve, on a non-binding advisory basis, the compensation of named executive officers.
Shareholders may submit proposals for the 2027 meeting by December 23, 2026, and must follow advance notice procedures for other business.
Board of directors and corporate governance
The Board consists of nine members divided into three classes with staggered three-year terms.
Seven of nine directors are independent; the CEO also serves as Chairman.
Committees include Audit, Compensation, Nominating and Corporate Governance, and Science, Innovation and Technology, all comprised of independent directors.
The Board values diversity in background and experience, though no formal diversity policy exists.
Latest events from Scholar Rock
- FDA accepted apitegromab BLA; net loss rose, cash reserves strong for 2026 launches.SRRK
Q1 20267 May 2026 - 2026 launches are on track, with strong liquidity and managed regulatory and supply risks.SRRK
Q4 20251 May 2026 - Key votes include director elections, auditor ratification, and executive pay approval.SRRK
Proxy filing23 Apr 2026 - BLA resubmission for Apitegromab offers dual approval paths and strong launch readiness.SRRK
Status update31 Mar 2026 - Apitegromab targets a 2026 U.S. launch after regulatory delays, with global expansion and strong financials.SRRK
Leerink Global Healthcare Conference 202628 Mar 2026 - Preparing for global SMA launches with strong clinical data and expanded pipeline.SRRK
Barclays 28th Annual Global Healthcare Conference12 Mar 2026 - 2026 launches for apitegromab expected after facility remediation, with global expansion planned.SRRK
TD Cowen 46th Annual Health Care Conference4 Mar 2026 - Transformational SMA data and robust launch plans set the stage for 2025 and pipeline growth.SRRK
Piper Sandler 36th Annual Healthcare Conference3 Feb 2026 - Transformative clinical milestones in SMA and obesity set the stage for commercial success.SRRK
Goldman Sachs 45th Annual Global Healthcare Conference3 Feb 2026